Cargando…

NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585731/
https://www.ncbi.nlm.nih.gov/pubmed/34785883
http://dx.doi.org/10.1007/s40274-021-08193-6
_version_ 1784597742421540864
collection PubMed
description
format Online
Article
Text
id pubmed-8585731
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85857312021-11-12 NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 PharmacoEcon Outcomes News News Item Springer International Publishing 2021-11-13 2021 /pmc/articles/PMC8585731/ /pubmed/34785883 http://dx.doi.org/10.1007/s40274-021-08193-6 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News Item
NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
title NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
title_full NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
title_fullStr NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
title_full_unstemmed NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
title_short NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
title_sort nz's pharmac to fund baricitinib for moderate-to-severe covid-19
topic News Item
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585731/
https://www.ncbi.nlm.nih.gov/pubmed/34785883
http://dx.doi.org/10.1007/s40274-021-08193-6